In late March 2009, Arena Pharmaceuticals (Nasdaq: ARNA) will announce results from the first of three Phase 3 Lorcaserin trials, an obesity drug candidate that selectively targets the serotonin receptors in the brain responsible for regulating appetite and satiety. The results may provide valuable insight into the efficacy and potential of competing products.

Users of Revere Healthcare can quickly identify several other biotechs with late stage obesity drugs under development. Two of these biotechs are VIVUS, Inc. (Nasdaq: VVUS) and Orexigen Therapeutics, Inc. (Nasdaq: OREX), developers of Qnexa and Contrave respectively.

Getting a drug approved by the FDA is a long and difficult process filled with uncertainty. Likewise, investors in biotechs are similarly exposed to the risks associated with the FDA approval process. Revere Healthcare offers a suite of data, reports, and analytics designed to help investors identify relevant opportunities, sharpen their understanding of the competitive landscape, and make better decisions.

For additional information on  Revere Healthcare , please contact our Research, Sales, and Customer Support Teams.

Sincerely,

Revere Research Team

CONTACTS
Research: research@reveredata.com
Sales: sales@reveredata.com
Customer Support: support@reveredata.com

DISCLAIMER
Revere Data, LLC is an independent provider of investment research and information and does not offer investment advice. Any mention of a specific company is not a recommendation to buy or sell a security of that company. Revere Data, LLC permits its analysts and members of their immediate families to invest and trade in the securities of the companies in the industry and industries covered by Revere Data, LLC. Though Revere Data, LLC is not required to be a registered investment advisor under the Investment Advisor Act of 1940 or as an investment advisor with any state, Revere Data, LLC voluntarily applies relevant and pertinent rules and procedures adopted by the NYSE and NASD as may be approved from time to time by the SEC relating to the issues of analyst independence and objectivity.